MVision AI
MVision develops technology that improves the treatment of various types of cancer by using artificial intelligence and machine learning. The company has been built on the idea to be an impactful organisation by bringing AI assisted diagnosis and treatment to whoever needs it, especially in developing countries. This dramatically improves treatment outcome and saves money. The founding team consists of AI PhD’s, data platform architects and physicists with experience from companies such as Varian Medical Systems and GE healthcare.
MVision AI
MVision develops technology that improves the treatment of various types of cancer by using artificial intelligence and machine learning. The company has been built on the idea to be an impactful organisation by bringing AI assisted diagnosis and treatment to whoever needs it, especially in developing countries. This dramatically improves treatment outcome and saves money. The founding team consists of AI PhD’s, data platform architects and physicists with experience from companies such as Varian Medical Systems and GE healthcare.
TL;DR
Location & founding year: Helsinki; founded 2017
Product focus: AI-powered SaaS for radiotherapy treatment planning (auto-contouring, dose prediction, integrated workflow)
Recent funding: Post-seed / Seed round on 2023-03-23 (~€5.4M reported)
Team size (reported): 54 employees
Regulatory & distribution: Multiple regulatory clearances and international distribution partnerships
Company Overview
Problem Domain
Radiotherapy treatment planning for cancer care
Founded
2017
Industry
Healthtech / Medical AI
Funding Track Record
Crunchbase lists an Angel round on May 23, 2018
Crunchbase lists a Pre-Seed round on Jan 7, 2020; Dealroom records a 2020 seed of $1.65M
5.4M EUR
Reported post-seed / seed round led by J12 Ventures and Voima Ventures
Investor Signal
“Participating investors include Voima Ventures, J12 (J12 Ventures), Icebreaker.vc, Nuard Ventures and angel investors”